Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05725-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Salvatore Leotta und 27 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and BMT Unit, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico-San Marco", Catania, Italy. leotta3@yahoo.it. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasm, Residual, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Blinatumomab is a bispecific T-cell engager approved for relapsed/refractory and minimal residual disease positive B-cell Acute Lymphoblastic Leukemia. We conducted a retrospective study evaluating the outcome of Blinatumomab. The impact of clinical and treatment-related variables on cumulative incidence of relapse/progression (CIRP), event-free (EFS) and overall survival (OS) was analyzed. From January 2016 to December 2022 50 Ph'- (37) and Ph+ (13) B-ALL patients received Blinatumomab. The median age was 37. Indications to blinatumomab were relapsed/refractory B-ALL in 29 and MRD-positive in 21 patients. Blinatumomab was the 2nd and 3rd line in 40 and in 10 patients, respectively. Twenty patients were treated pre-transplantation, ten were treated for relapse after transplant, twenty were not eligible for transplant. Out of 29 patients treated for relapsed/refractory disease, 16 (55%) achieved complete response and 12 achieved MRD-negativity. Out of 21 patients treated for MRD, 16 (76%) achieved MRD-negativity. At a median follow-up of 46 months the median EFS and OS were 11.5 and 16.2 months. The CIRP was 50%. In univariate analysis age, disease-status (overt vs. minimal disease) at blinatumomab, bridging to transplant after blinatumomab and MRD-response resulted significant for EFS and OS. In multivariate analysis only disease-status and MRD-response retained significance both for EFS and OS. Disease-status and MRD-response resulted significant for EFS and OS also after censoring at HSCT. This retrospective study on B-ALL patients treated with blinatumomab confirms a superior outcome for MRD-responsive over MRD non-responsive patients. Survival depends also on the disease-status prior treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and BMT Unit, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico-San Marco", Catania, Italy. leotta3@yahoo.it.
- Divisione di Ematologia - Azienda Ospedaliero, Universitaria Policlinico "G. Rodolico - San Marco", Via Santa Sofia, 78, Catania, 95123, Italy. leotta3@yahoo.it.
- Hematology and BMT Unit, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico-San Marco", Catania, Italy.
- Oncohematology Unit - AO Villa Sofia - Cervello, Palermo, Italy.
- Hematology Unit, Ospedale "La Maddalena", Palermo, Italy.
- Haematology and Stem Cell Transplant Unit, Presidio Ospedaliero "Vito Fazzi", Lecce, Italy.
Zitieren
APA
Leotta, S., Markovic, U., Duminuco, A., Mulè, A., Porretto, F., Federico, V., Gentile, M., Pastore, D., Nigro, L. L., Selleri, C., Serio, B., Calafiore, V., Patti, C., Mauro, E., Vetro, C., Maugeri, C., Parisi, M., Fiumara, P., Parrinello, L., …, & Milone, G. (2024). Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05725-9
Vancouver
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, et al. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05725-9
BibTeX
@article{Leotta2024,
author = {Leotta, Salvatore and Markovic, Uros and Duminuco, Andrea and Mulè, Antonino and Porretto, Ferdinando and Federico, Vincenzo and Gentile, Massimo and Pastore, Domenico and Nigro, Luca Lo and Selleri, Carmine and Serio, Bianca and Calafiore, Valeria and Patti, Caterina and Mauro, Elisa and Vetro, Calogero and Maugeri, Cinzia and Parisi, Marina and Fiumara, Paolo and Parrinello, Laura and Marino, Sara and Scuderi, Grazia and Garibaldi, Bruno and Musso, Maurizio and Renzo, Nicola Di and Vigna, Ernesto and Martino, Enrica Antonia and Raimondo, Francesco Di and Milone, Giuseppe},
title = {Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05725-9}
}
EUVIMED